The performance of companies tied to the drug's past presents a challenging investment picture . While the initial surge generated substantial gains, generic alternatives have significantly eroded sales . Investing in connected pharmaceutical businesses now requires a thorough assessment of intellectual property safeguards, evolving healthcare chan